Security
Xenon Pharmaceuticals Inc. Common Shares · XENE
XENENASDAQCommon stockCurrentCIK 1582313Updated Nov 10, 2026
XENE price & chart
Loading TradingView…
NASDAQ:XENE on TradingView ↗About the company
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
In the news
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Xenon to Present at Upcoming Investor Conferences ↗
Seeking Alpha
Xenon plans X-FIRST study in Q1 2027 as AZK NDA advances, with $1.2B cash into 2029 ↗
Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript ↗
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate ↗
SEC disclosures
Xenon Pharmaceuticals Inc. files 8-K: Material Event ↗
Recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
SCHEDULE 13G/A - filed by FMR LLC regarding Xenon Pharmaceuticals Inc.
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 607,836,000Source | 835,901,000Source | 1,295,772,000Source | 674,281,000Source | 884,011,000Source | 1,386,810,000Source | 743,280,000Source | 919,023,000Source | 633,163,000Source | 798,139,000Source | 964,798,000Source | 754,146,000Source |
| Property, Plant and Equipment, NetUSD | 8,887,000Source | 10,162,000Source | 7,774,000Source | 9,205,000Source | 10,138,000Source | 8,294,000Source | 9,696,000Source | 9,393,000Source | 8,721,000Source | 10,278,000Source | 9,653,000Source | 6,500,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 104,514,000Source | 87,621,000Source | 119,527,000Source | 135,381,000Source | 136,734,000Source | 545,867,000Source | 116,657,000Source | 58,896,000Source | 199,163,000Source | 142,712,000Source | 148,643,000Source | 57,242,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 938,000Source | — | — | 853,000Source | — | — | 833,000Source | — | 1,469,000Source | 874,000Source | 986,000Source |
| Assets, CurrentUSD | 480,137,000Source | 659,639,000Source | 945,868,000Source | 500,252,000Source | 728,089,000Source | 1,106,632,000Source | 565,537,000Source | 707,204,000Source | 560,649,000Source | 635,264,000Source | 644,962,000Source | 600,298,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 17,057,000Source | 4,686,000Source | 13,553,000Source | 11,610,000Source | 5,701,000Source | 10,720,000Source | 7,259,000Source | 6,769,000Source | 10,392,000Source | 6,890,000Source | 6,006,000Source | 7,225,000Source |
| Operating Lease, Right-of-Use AssetUSD | 6,960,000Source | 8,258,000Source | 5,385,000Source | 7,290,000Source | 8,573,000Source | 6,288,000Source | 7,617,000Source | 8,884,000Source | 6,626,000Source | 7,939,000Source | 9,193,000Source | 10,406,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 48,325,000Source | 38,094,000Source | 53,376,000Source | 40,303,000Source | 39,964,000Source | 48,991,000Source | 39,323,000Source | 31,325,000Source | 51,403,000Source | 43,236,000Source | 36,877,000Source | 32,649,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,475,371,000Source | 1,441,814,000Source | 2,426,619,000Source | 1,469,196,000Source | 1,440,458,000Source | 2,421,833,000Source | 1,460,850,000Source | 1,438,961,000Source | 1,598,571,000Source | 1,456,836,000Source | 1,436,374,000Source | 1,065,136,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,140,119,000Source | -833,785,000Source | -1,458,418,000Source | -1,049,223,000Source | -770,995,000Source | -1,347,682,000Source | -964,517,000Source | -713,071,000Source | -1,245,380,000Source | -899,470,000Source | -665,140,000Source | -482,747,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 477,000Source | 1,336,000Source | -2,656,000Source | 113,000Source | -2,212,000Source | -1,211,000Source | -836,000Source | -1,769,000Source | 335,000Source | -1,612,000Source | -77,000Source | -3,000,000Source |
| Stockholders' Equity Attributable to ParentUSD | 559,511,000Source | 797,807,000Source | 1,242,396,000Source | 633,978,000Source | 844,047,000Source | 1,337,819,000Source | 703,957,000Source | 887,698,000Source | 581,760,000Source | 754,903,000Source | 927,921,000Source | 721,497,000Source |
| Additional Paid in Capital, Common StockUSD | 223,782,000Source | 188,442,000Source | 276,851,000Source | 213,892,000Source | 176,796,000Source | 264,879,000Source | 208,460,000Source | 163,577,000Source | 228,234,000Source | 199,149,000Source | 156,764,000Source | 142,108,000Source |
| Liabilities and EquityUSD | 607,836,000Source | 835,901,000Source | 1,295,772,000Source | 674,281,000Source | 884,011,000Source | 1,386,810,000Source | 743,280,000Source | 919,023,000Source | 633,163,000Source | 798,139,000Source | 964,798,000Source | 754,146,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 38,335,000Source | 29,695,000Source | 45,009,000Source | 33,047,000Source | 31,285,000Source | 39,815,000Source | 32,030,000Source | 22,223,000Source | 41,792,000Source | 35,590,000Source | 27,273,000Source | 22,702,000Source |
| Operating Lease, Liability, CurrentUSD | 1,495,000Source | 1,387,000Source | 1,338,000Source | 1,459,000Source | 1,354,000Source | 1,561,000Source | 1,382,000Source | 1,323,000Source | 1,532,000Source | 1,369,000Source | 1,299,000Source | 488,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,832,000Source | 8,399,000Source | 5,080,000Source | 7,256,000Source | 8,679,000Source | 5,930,000Source | 7,293,000Source | 9,102,000Source | 6,412,000Source | 7,646,000Source | 9,604,000Source | 9,947,000Source |
| Other Liabilities, NoncurrentUSD | 3,158,000Source | — | 3,287,000Source | — | — | 3,246,000Source | — | — | 3,199,000Source | — | — | — |
| Accrued Liabilities, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -102,302,000Source | -65,047,000Source | -345,910,000Source | -234,330,000Source | -182,393,000Source | -125,373,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 13,705,000Source | 13,002,000Source | 16,732,000Source | 13,713,000Source | 16,894,000Source | 12,174,000Source | 53,707,000Source | 50,717,000Source | 32,372,000Source | 20,376,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | 614,000Source | -130,000Source | -1,757,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 447,000Source | -1,213,000Source | -3,198,000Source | -8,864,000Source | -292,000Source | -44,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -88,897,000Source | -61,652,000Source | -279,118,000Source | -181,389,000Source | -145,327,000Source | -98,430,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -407,282,000Source | 34,510,000Source | 217,998,000Source | 165,000,000Source | -117,170,000Source | -296,003,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 133,000Source | 43,000Source | 799,000Source | 3,075,000Source | 5,617,000Source | 2,894,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 843,013,000Source | 1,151,000Source | 117,113,000Source | 12,130,000Source | 353,522,000Source | 278,471,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 346,704,000Source | -26,055,000Source | 56,451,000Source | -5,931,000Source | 91,401,000Source | -118,446,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 8,423,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -130,000Source | -64,000Source | 458,000Source | -1,672,000Source | 376,000Source | -2,484,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 13,705,000Source | 13,002,000Source | 16,732,000Source | 13,713,000Source | 16,894,000Source | 12,174,000Source | 53,707,000Source | 50,717,000Source | 32,372,000Source | 20,376,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -89,000Source | 237,000Source | -311,000Source | 1,698,000Source | 548,000Source | 35,000Source | 1,348,000Source | -1,064,000Source | 199,000Source | -1,891,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | 204,000Source | -182,000Source | -73,000Source | -745,000Source | 640,000Source | -2,729,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 19,282,000Source | 16,706,000Source | 23,931,000Source | 19,244,000Source | 23,820,000Source | 19,038,000Source | 79,632,000Source | 68,904,000Source | 46,542,000Source | 32,810,000Source |
| Income Tax Expense (Benefit)USD | — | — | 677,000Source | -320,000Source | -585,000Source | -626,000Source | -2,571,000Source | 427,000Source | 1,016,000Source | -4,089,000Source | -292,000Source | 118,000Source |
| Investment Income, InterestUSD | — | — | 6,206,000Source | 10,329,000Source | 12,145,000Source | 7,199,000Source | 6,907,000Source | 8,083,000Source | 26,828,000Source | 41,943,000Source | 27,620,000Source | 8,713,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | 400,000Source | -518,000Source | -625,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -90,896,000Source | -62,790,000Source | -110,736,000Source | -84,706,000Source | -102,302,000Source | -65,047,000Source | -345,910,000Source | -234,330,000Source | -182,393,000Source | -125,373,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | -234,330,000Source | -182,393,000Source | -124,936,000Source |
| Nonoperating Income (Expense)USD | — | — | 6,117,000Source | 10,566,000Source | 11,834,000Source | 8,897,000Source | 7,455,000Source | 8,118,000Source | 28,176,000Source | 40,879,000Source | 31,369,000Source | 3,888,000Source |
| Operating ExpensesUSD | — | — | 96,336,000Source | 73,676,000Source | 123,155,000Source | 94,229,000Source | 112,328,000Source | 80,238,000Source | 380,570,000Source | 279,298,000Source | 214,054,000Source | 138,577,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 5,487,000Source | 1,151,000Source | 4,962,000Source | 47,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 7,500,000Source | 7,500,000Source | — | — | 9,434,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -96,336,000Source | -73,676,000Source | -123,155,000Source | -94,229,000Source | -112,328,000Source | -72,738,000Source | -373,070,000Source | -279,298,000Source | -214,054,000Source | -129,143,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -90,219,000Source | -63,110,000Source | -111,321,000Source | -85,332,000Source | -104,873,000Source | -64,620,000Source | -344,894,000Source | -238,419,000Source | -182,685,000Source | -125,255,000Source |
| Income Tax Expense (Benefit)USD | — | — | 677,000Source | -320,000Source | -585,000Source | -626,000Source | -2,571,000Source | 427,000Source | 1,016,000Source | -4,089,000Source | -292,000Source | 118,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -90,896,000Source | -62,790,000Source | -110,736,000Source | -84,706,000Source | -102,302,000Source | -65,047,000Source | -345,910,000Source | -234,330,000Source | -182,393,000Source | -125,373,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.15Source | -0.81Source | -1.11Source | -1.07Source | -1.17Source | -0.83Source | -4.36Source | -3.01Source | -2.73Source | -2.06Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.15Source | -0.81Source | -1.11Source | -1.07Source | -1.17Source | -0.83Source | -4.36Source | -3.01Source | -2.73Source | -2.06Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 79,247,976Source | 77,926,205Source | 99,609,804Source | 78,953,445Source | 87,345,717Source | 78,687,503Source | 79,253,751Source | 77,894,643Source | 66,889,005Source | 60,542,142Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 79,247,976Source | 77,926,205Source | 99,609,804Source | 78,953,445Source | 87,345,717Source | 78,687,503Source | 79,253,751Source | 77,894,643Source | 66,889,005Source | 60,542,142Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 4,214,000Source | 4,775,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 587,000Source | 659,000Source | 2,543,000Source | 2,560,000Source | 3,541,000Source | 1,624,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -89,000Source | 237,000Source | -311,000Source | 1,698,000Source | 548,000Source | 35,000Source | 1,348,000Source | -1,064,000Source | 199,000Source | -1,891,000Source |
| General and Administrative ExpenseUSD | — | — | 19,282,000Source | 16,706,000Source | 23,931,000Source | 19,244,000Source | 23,820,000Source | 19,038,000Source | 79,632,000Source | 68,904,000Source | 46,542,000Source | 32,810,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -351,065,000Source | -243,410,000Source | — | — |
| Investment Income, InterestUSD | — | — | 6,206,000Source | 10,329,000Source | 12,145,000Source | 7,199,000Source | 6,907,000Source | 8,083,000Source | 26,828,000Source | 41,943,000Source | 27,620,000Source | 8,713,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | 400,000Source | -518,000Source | -625,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | -234,330,000Source | -182,393,000Source | -124,936,000Source |
| Nonoperating Income (Expense)USD | — | — | 6,117,000Source | 10,566,000Source | 11,834,000Source | 8,897,000Source | 7,455,000Source | 8,118,000Source | 28,176,000Source | 40,879,000Source | 31,369,000Source | 3,888,000Source |
| Operating ExpensesUSD | — | — | 96,336,000Source | 73,676,000Source | 123,155,000Source | 94,229,000Source | 112,328,000Source | 80,238,000Source | 380,570,000Source | 279,298,000Source | 214,054,000Source | 138,577,000Source |
| Other General and Administrative ExpenseUSD | — | — | 6,715,000Source | 4,557,000Source | 8,025,000Source | 6,014,000Source | 7,801,000Source | 5,531,000Source | 26,794,000Source | 20,657,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 77,054,000Source | 56,970,000Source | 99,224,000Source | 74,985,000Source | 88,508,000Source | 61,200,000Source | 300,938,000Source | 210,394,000Source | 167,512,000Source | 105,767,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 7,500,000Source | 7,500,000Source | — | — | 9,434,000Source |
Filing attachments
xene-ex99_1.htm · 8-K · 2026-11-09
Exhibit 99.1 Xenon Reports Q3 2026 Financial Results and Provides Business Update • New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 • Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies and planned Q1 2027 initiation of Phase 3b/4 X-FIRST study evaluating azetukalner as first add-on ASM • Enrollment in Phase 3 X-NOVA2 study of azetukalner in MDD completed with topline data readout…
Read attachment ↗xene-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 xene-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xenon Reports Q2 2026 Financial Results and Provides Business Update • NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA • Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue to enroll • Three Phase 3 studies of azetukalner in neuropsychiatry continue to advance, with topline data from X-NOVA2 study in MDD expected H1 2027 • Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120)…
Read attachment ↗xene-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 xene-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xenon Reports Q1 2026 Financial Results and Provides Business Update • Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026 • Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and depression indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 • Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidat…
Read attachment ↗xene-ex99_1.htm · 8-K · 2026-03-13
EX-99.1 2 xene-ex99_1.htm EX-99.1 EX-99.1 March 13, 2026 Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission RE: Xenon Pharmaceuticals Inc. Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders: Date of meeting: June 2, 2026 Record date for notice: …
Read attachment ↗d97906dex41.htm · 8-K · 2026-03-12
EX-4.1 3 d97906dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Number of Shares: (subject to adjustment) Warrant No. Original Issue Date: [ ], 2026 XENON PHARMACEUTICALS INC. Xenon Pharmaceuticals Inc, a corporation continued under the federal laws of Canada (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”…
Read attachment ↗d107087dex991.htm · 8-K · 2026-03-09
EX-99.1 2 d107087dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006) X-TOLE2 outperformed Phase 2b X-TOLE study, with a placebo-adjusted MPC of -42.7% in 25 mg group in X-TOLE2 compared …
Read attachment ↗